Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Clazakizumab for Antibody Mediated Rejection
Recruiting1 awardPhase 3
Cincinnati, Ohio
This trial tests clazakizumab, a drug that blocks IL-6, in kidney transplant patients with chronic rejection. The goal is to see if it can reduce the immune system's attack on the transplanted kidney and improve its function. Clazakizumab is being tested for its potential to counteract rejection in kidney transplant patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service